Medical Access in Spain

Psilocybin and psilocin are listed in Spain's psychotropic-control framework. Patient access should be described as clinical-trial or special-situations only, with no public evidence of a standing national compassionate-use programme. [1]BOE consolidated psychotropics decree [2]AEMPS special situations access route [3]COMP006 ClinicalTrials.gov record

MDMA is controlled in Spain. The historically important Madrid PTSD pilot does not create current routine access or reimbursement, and any lawful use remains research or exceptional-access based. [1]BOE consolidated psychotropics decree [2]Bouso MDMA PTSD pilot paper [3]AEMPS special situations access route

Spravato is EU-authorised and listed in Spain. BIFIMED shows public financing from 1 November 2022 for adults aged 18-74 with severe TRD who have failed at least three antidepressant strategies, including one combination or augmentation strategy. The psychiatric-emergency indication is not publicly financed. [1]EMA Spravato EPAR [2]CIMA Spravato product information [3]BIFIMED Spravato financing entry

Racemic ketamine is authorised as an injectable anaesthetic medicine, not as an antidepressant. Psychiatric use is therefore off-label, and no national depression-specific reimbursement route equivalent to Spravato was identified. [1]CIMA Ketolar product information [2]BIFIMED Spravato financing entry

DMT is listed in Spain's controlled psychotropic framework. Research on DMT-related mechanisms exists historically through the ayahuasca line, but this does not translate into routine medical access or reimbursement. [1]BOE consolidated psychotropics decree [2]Riba ayahuasca human pharmacology paper

5-MeO-DMT/mebufotenin should be framed as investigational in Spain. Barcelona-linked participation in GH001 research is a scientific signal, not an authorised or reimbursed treatment pathway. [1]GH001 phase 2b publication notice [2]AEMPS special situations access route

No public evidence was identified for routine authorised ibogaine treatment or reimbursement in Spain. Any claim of access should be verified against AEMPS permissions and Spanish controlled-substance rules. [1]AEMPS narcotics and psychotropics page [2]AEMPS special situations access route

Ayahuasca is not an authorised medicine in Spain and recent court discussion should not be read as national medical legalisation. The safest access description is legally contested non-medical use, with no reimbursement pathway. [1]BOE consolidated psychotropics decree [2]ICEERS Spain ayahuasca legal note

Mescaline is listed in Spain's psychotropic controls. No authorised medical access or reimbursement pathway was identified. [1]BOE consolidated psychotropics decree

2C-family phenethylamines should be treated as controlled or unauthorised in Spain for medical access purposes. No routine clinical pathway or reimbursement route was identified. [1]BOE consolidated psychotropics decree [2]AEMPS narcotics and psychotropics page